Vol 5, No 23 (December 2017): Annals of Translational Medicine

Original Article

Detection of MET amplification in gastroesophageal tumor specimens using IQFISH
Jan Trøst Jørgensen, Karsten Bork Nielsen, Jens Mollerup, Anna Jepsen, Ning Go


River blindness goes beyond the eye: autoimmune antibodies, cross-reactive with Onchocerca volvulus antigen, detected in brain of patients with Nodding syndrome
Christoph Kaiser, Sébastien D. S. Pion
Alectinib in untreated anaplastic lymphoma kinase-positive nonsmall cell lung cancer
Anne-Marie Ruppert, Xavier Mignard, Marie Wislez
New evidence for nodding disease as an autoimmune reaction to Onchocerca volvulus
Michael J. Boivin
Antibody-drug conjugate targeting protein tyrosine kinase 7, a receptor tyrosine kinase-like molecule involved in WNT and vascular endothelial growth factor signaling: effects on cancer stem cells, tumor microenvironment and whole-body homeostasis
Masaru Katoh
Creative technology advances tissue preservation
Mandi J. Lopez
Drugs targeting protease-activated receptor-4 improve the antithrombotic therapeutic window
Shauna L. French, Justin R. Hamilton
Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction
Ahsan A. Khan, Gregory Y. H. Lip
Prediction models to advance individualized resuscitation in trauma hemorrhage and acute traumatic coagulopathy (ATC): even the longest journey starts with first steps—Lao-Tzu (Chinese philosopher)
Marc Maegele
Novel regulators of PD-L1 expression in cancer: CMTM6 and CMTM4—a new avenue to enhance the therapeutic benefits of immune checkpoint inhibitors
Denira Imamovic, Semir Vranic
Predictors of response and resistance to checkpoint inhibitors in solid tumors
Sanjana V. Rao, Amy E. Moran, Julie N. Graff
Nrf2: a promising trove for diabetic wound healing
Amruta Jindam, Veera Ganesh Yerra, Ashutosh Kumar
Sodium-glucose cotransporter 2 inhibitors and death and heart failure in type 2 diabetes
Hidekatsu Yanai
Lysosomal function in β-cell survival during glucolipotoxicity
Ana Batista- Gonzalez, Rajat Singh
Telomeric zinc-finger associated protein (TZAP): a new player in telomere diseases?
Benedetta Donati, Luca Valenti
Canagliflozin lowers blood sugar, but does it also lower cardiovascular risk? Maybe not
Thomas F. Heston, Anndres H. Olson, Nicholas R. Randall
Comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors: SGLT2 inhibitors in the real world
Richard J. MacIsaac, Elif I. Ekinci
Semaglutide—the “new kid on the block” in the field of glucagonlike peptide-1 receptor agonists?
Cristian Guja, Rucsandra Dănciulescu Miulescu
Cardiovascular outcome studies with glucagon-like peptide 1 receptor agonists—what will REWIND add?
Keith C. Ferdinand, Indrajeet Mahata
The ODYSSEY DM-DYSLIPIDEMIA trial: confirming the benefits of alirocumab in diabetic mixed dyslipidemia
Paul Chan, Li Shao, Brian Tomlinson, Zhong-Min Liu
Empagliflozin reduces albuminuria—a promise for better cardiorenal protection from the EMPA-REG OUTCOME trial
Rikke Borg, Frederik Persson


Liquid biopsy for ctDNA to revolutionize the care of patients with early stage lung cancers
Bob T. Li, Dennis Stephens, Jamie E. Chaft, Charles M. Rudin, David R. Jones, Valerie W. Rusch, Andreas Rimner, James M. Isbell

Letter to the Editor

Radiation risk from lung cancer screening
Cristiano Rampinelli, Paolo De Marco, Massimo Bellomi